C07K14/205

MODIFIED CARRIER PROTEINS FOR O-LINKED GLYCOSYLATION

Carrier proteins modified to incorporate one or more pilin glycotags and applications thereof for O-linked glycosylation are provided. In particular, a modified carrier protein comprising a carrier protein that comprises at least one GlycoTag, wherein the at least one GlycoTag is a Neisseria gonorrhoeae PglL GlycoTag (NgGlycoTag), Neisseria lactamica PglL GlycoTag (NlGlycoTag), or Neisseria shayeganii GlycoTag (NsGlycoTag), or combinations thereof is provided, together with nucleic acids and vectors encoding the modified carrier protein, host cells comprising these modofoed carrier proteins or nucleic acids encoding them, bioconjugates, methods of making bioconjugates and uses of the bioconjugates.

MODIFIED CARRIER PROTEINS FOR O-LINKED GLYCOSYLATION

Carrier proteins modified to incorporate one or more pilin glycotags and applications thereof for O-linked glycosylation are provided. In particular, a modified carrier protein comprising a carrier protein that comprises at least one GlycoTag, wherein the at least one GlycoTag is a Neisseria gonorrhoeae PglL GlycoTag (NgGlycoTag), Neisseria lactamica PglL GlycoTag (NlGlycoTag), or Neisseria shayeganii GlycoTag (NsGlycoTag), or combinations thereof is provided, together with nucleic acids and vectors encoding the modified carrier protein, host cells comprising these modofoed carrier proteins or nucleic acids encoding them, bioconjugates, methods of making bioconjugates and uses of the bioconjugates.

Campylobacter immunogenic compositions and uses thereof

The present disclosure provides immunogenic compositions against Campylobacter and methods for using the immunogenic composition to generate an immune response against Campylobacter and/or reduce intestinal colonization by Campylobacter.

Campylobacter immunogenic compositions and uses thereof

The present disclosure provides immunogenic compositions against Campylobacter and methods for using the immunogenic composition to generate an immune response against Campylobacter and/or reduce intestinal colonization by Campylobacter.

Composition for inhibiting growth of bacterium having menaquinone synthesis pathway through futalosine or futalosine derivative
11337947 · 2022-05-24 · ·

The present invention provides a composition for inhibiting proliferation of a bacterium provided with a menaquinone synthesis route via futalosine or a futalosine derivative, which contains a fatty acid having 18 carbon atoms and a hydroxyl group at the 10-position as an active ingredient. Furthermore, the present invention provides a composition for preventing or treating a disease caused by a bacterium provided with a menaquinone synthesis route via futalosine or a futalosine derivative.

Composition for inhibiting growth of bacterium having menaquinone synthesis pathway through futalosine or futalosine derivative
11337947 · 2022-05-24 · ·

The present invention provides a composition for inhibiting proliferation of a bacterium provided with a menaquinone synthesis route via futalosine or a futalosine derivative, which contains a fatty acid having 18 carbon atoms and a hydroxyl group at the 10-position as an active ingredient. Furthermore, the present invention provides a composition for preventing or treating a disease caused by a bacterium provided with a menaquinone synthesis route via futalosine or a futalosine derivative.

Food safety vaccine to control <i>Salmonella enterica </i>and reduce <i>Campylobacter </i>in poultry

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation, regulated expression of one or more antigens of interest, and/or N-glycan modification of secreted/surface antigens.

Food safety vaccine to control <i>Salmonella enterica </i>and reduce <i>Campylobacter </i>in poultry

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation, regulated expression of one or more antigens of interest, and/or N-glycan modification of secreted/surface antigens.

Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
11166986 · 2021-11-09 · ·

The present invention is directed to polypeptides and compositions thereof useful for the prevention or treatment of an inflammatory bowel disease in particular Crohn's disease or ulcerative colitis (UC), and of coeliac disease. More particularly, the invention relates to agents and compositions thereof that useful for the prevention and treatment of hypersensitivity and/or hyperirritability of the colon and/or small intestine.

Use of heliocbacter pylori extract for treating or preventing inflammatory bowel diseases and coeliac disease
11166986 · 2021-11-09 · ·

The present invention is directed to polypeptides and compositions thereof useful for the prevention or treatment of an inflammatory bowel disease in particular Crohn's disease or ulcerative colitis (UC), and of coeliac disease. More particularly, the invention relates to agents and compositions thereof that useful for the prevention and treatment of hypersensitivity and/or hyperirritability of the colon and/or small intestine.